Literature DB >> 25900426

Genetics of cerebral cavernous malformations: current status and future prospects.

H Choquet1, L Pawlikowska, M T Lawton, H Kim.   

Abstract

Cerebral cavernous malformations (CCM) are vascular lesions which affect up to 0.5% of the general population, predisposing to headaches, seizures, cerebral hemorrhages and focal neurological deficits. CCM occurs in both sporadic and familial forms; familial cases follow an autosomal-dominant mode of inheritance and are caused by mutations in CCM1 (KRIT1), CCM2 (MGC4607), or CCM3 (PDCD10). Somatic mutations within the three CCM genes have been identified in CCM lesions from both sporadic and familial patients. We reviewed articles published in PubMed in English prior to March 2015 and provide an update on CCM mutations and the screening strategies used to identify them. Further, we summarize the specific clinical features related to CCM genotypes. As 5% to 15% of familial CCM cases remain genetically unexplained, we also discuss future approaches to expand understanding of the genetic architecture of CCM. Finally, we discuss possible genetic modifiers of CCM disease severity and progression. Understanding the genetic architecture of CCM is essential for an earlier diagnosis of the disease, predictive testing of at-risk patients, and design of targeted medical therapies of which there are currently none available.

Entities:  

Mesh:

Year:  2015        PMID: 25900426      PMCID: PMC4461471     

Source DB:  PubMed          Journal:  J Neurosurg Sci        ISSN: 0390-5616            Impact factor:   2.279


  87 in total

1.  Multiple cerebral cavernous malformations and a novel CCM3 germline deletion in a German family.

Authors:  Chi-un Choe; Florence Riant; Christian Gerloff; Elisabeth Tournier-Lasserve; Michael Orth
Journal:  J Neurol       Date:  2010-07-11       Impact factor: 4.849

2.  Highly variable intrafamilial manifestations of a CCM3 mutation ranging from acute childhood cerebral haemorrhage to late-onset meningiomas.

Authors:  C Fauth; K Rostasy; M Rath; E Gizewski; A G Lederer; U Sure; J Zschocke; U Felbor
Journal:  Clin Neurol Neurosurg       Date:  2014-11-06       Impact factor: 1.876

3.  A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease.

Authors:  David A McDonald; Robert Shenkar; Changbin Shi; Rebecca A Stockton; Amy L Akers; Melanie H Kucherlapati; Raju Kucherlapati; James Brainer; Mark H Ginsberg; Issam A Awad; Douglas A Marchuk
Journal:  Hum Mol Genet       Date:  2010-10-11       Impact factor: 6.150

4.  Deletions in CCM2 are a common cause of cerebral cavernous malformations.

Authors:  Christina L Liquori; Michel J Berg; Ferdinando Squitieri; Tracey P Leedom; Louis Ptacek; Eric W Johnson; Douglas A Marchuk
Journal:  Am J Hum Genet       Date:  2006-11-14       Impact factor: 11.025

5.  An association between autosomal dominant cerebral cavernomas and a distinctive hyperkeratotic cutaneous vascular malformation in 4 families.

Authors:  P Labauge; O Enjolras; J J Bonerandi; S Laberge; M Dandurand; J M Joujoux; E Tournier-Lasserve
Journal:  Ann Neurol       Date:  1999-02       Impact factor: 10.422

6.  Cavernous malformations and hemorrhage risk.

Authors:  Douglas Kondziolka; Edward A Monaco; L Dade Lunsford
Journal:  Prog Neurol Surg       Date:  2012-12-11

7.  Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis.

Authors:  Amy L Akers; Eric Johnson; Gary K Steinberg; Joseph M Zabramski; Douglas A Marchuk
Journal:  Hum Mol Genet       Date:  2008-12-16       Impact factor: 6.150

8.  Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations.

Authors:  J Sirvente; O Enjolras; M Wassef; E Tournier-Lasserve; P Labauge
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-04-29       Impact factor: 6.166

9.  Spinal root arteriovenous malformations and same-segment cord cavernous malformation in familial cerebral cavernous malformation. Case report.

Authors:  Jorge Marcondes De Souza; Flavio S Domingues; Leila Chimelli; Judith Gault
Journal:  J Neurosurg Spine       Date:  2008-09

10.  Mutations within the MGC4607 gene cause cerebral cavernous malformations.

Authors:  C Denier; S Goutagny; P Labauge; V Krivosic; M Arnoult; A Cousin; A L Benabid; J Comoy; P Frerebeau; B Gilbert; J P Houtteville; M Jan; F Lapierre; H Loiseau; P Menei; P Mercier; J J Moreau; A Nivelon-Chevallier; F Parker; A M Redondo; J M Scarabin; M Tremoulet; M Zerah; J Maciazek; E Tournier-Lasserve
Journal:  Am J Hum Genet       Date:  2004-01-22       Impact factor: 11.025

View more
  20 in total

Review 1.  Cerebrovascular disorders associated with genetic lesions.

Authors:  Philipp Karschnia; Sayoko Nishimura; Angeliki Louvi
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

2.  Automated algorithm for counting microbleeds in patients with familial cerebral cavernous malformations.

Authors:  Xiaowei Zou; Blaine L Hart; Marc Mabray; Mary R Bartlett; Wei Bian; Jeffrey Nelson; Leslie A Morrison; Charles E McCulloch; Christopher P Hess; Janine M Lupo; Helen Kim
Journal:  Neuroradiology       Date:  2017-05-22       Impact factor: 2.804

3.  Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.

Authors:  Alexandra Russo; Marie Astrid Neu; Johanna Theruvath; Bettina Kron; Arthur Wingerter; Silla Hey-Koch; Yasemin Tanyildizi; Joerg Faber
Journal:  Childs Nerv Syst       Date:  2017-05-09       Impact factor: 1.475

Review 4.  Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases.

Authors:  Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Physiol Rev       Date:  2019-04-01       Impact factor: 37.312

5.  Compendium of causative genes and their encoded proteins for common monogenic disorders.

Authors:  Tucker L Apgar; Charles R Sanders
Journal:  Protein Sci       Date:  2021-09-21       Impact factor: 6.993

6.  High Prevalence of Spinal Cord Cavernous Malformations in the Familial Cerebral Cavernous Malformations Type 1 Cohort.

Authors:  M C Mabray; J Starcevich; J Hallstrom; M Robinson; M Bartlett; J Nelson; A Zafar; H Kim; L Morrison; B L Hart
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-28       Impact factor: 3.825

7.  Genome-Wide Sequencing Reveals Small Nucleolar RNAs Downregulated in Cerebral Cavernous Malformations.

Authors:  Souvik Kar; Kiran Kumar Bali; Arpita Baisantry; Robert Geffers; Christian Hartmann; Amir Samii; Helmut Bertalanffy
Journal:  Cell Mol Neurobiol       Date:  2018-07-10       Impact factor: 5.046

Review 8.  Blood-brain barrier-on-a-chip: Microphysiological systems that capture the complexity of the blood-central nervous system interface.

Authors:  Duc Tt Phan; R Hugh F Bender; Jillian W Andrejecsk; Agua Sobrino; Stephanie J Hachey; Steven C George; Christopher Cw Hughes
Journal:  Exp Biol Med (Maywood)       Date:  2017-02-14

9.  Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation.

Authors:  Miguel Alejandro Lopez-Ramirez; Catherine Chinhchu Lai; Shady Ibrahim Soliman; Preston Hale; Angela Pham; Esau J Estrada; Sara McCurdy; Romuald Girard; Riya Verma; Thomas Moore; Rhonda Lightle; Nicholas Hobson; Robert Shenkar; Orit Poulsen; Gabriel G Haddad; Richard Daneman; Brendan Gongol; Hao Sun; Frederic Lagarrigue; Issam A Awad; Mark H Ginsberg
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

10.  Clinical, neuroradiological and genetic findings in a cohort of patients with multiple Cerebral Cavernous Malformations.

Authors:  Silvia Lanfranconi; Lorenzo Piergallini; Dario Ronchi; Gloria Valcamonica; Giorgio Conte; Elena Marazzi; Giulia Manenti; Giulio Andrea Bertani; Marco Locatelli; Fabio Triulzi; Nereo Bresolin; Elisa Scola; Giacomo Pietro Comi
Journal:  Metab Brain Dis       Date:  2021-08-06       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.